Collectively, our results suggest that SLC26A3 acts as a tumor suppressor in CRC and downregulation of its expression may serve as a molecular biomarker for identifying CRC patients at high risk for poor prognosis. The gene discussed is SLC26A3; the disease is neoplasm.